Kezar Life Sciences, Inc.
4000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States
650 822 5600
https://www.kezarlifesciences.com
版塊: Healthcare
行業: Biotechnology
全職員工: 58
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Christopher J. Kirk Ph.D. | Co-Founder, CEO & Director | 644.68k | 無 | 1972 |
| Mr. John Franklin Fowler | Co-Founder & Director | 539.35k | 無 | 1972 |
| Mr. Marc L. Belsky | CFO & Secretary | 639.41k | 無 | 1955 |
| Dr. Nick Mordwinkin Ph.D., Pharm.D. | Chief Business Officer & Head of Strategy | 563.25k | 無 | 1981 |
| Dr. Jack Taunton Ph.D. | Co-Founder | 無 | 無 | 無 |
| Ms. Gitanjali Jain | Vice President of Investor Relations & External Affairs | 無 | 無 | 無 |
| Mr. Mark Schiller | Chief Legal Officer | 無 | 無 | 1980 |
| Dr. Neel K. Anand Ph.D. | Senior Vice President of Research & Drug Discovery | 無 | 無 | 無 |
| Mr. Zung To | Senior Vice President of Clinical Development | 無 | 無 | 無 |
| Ms. Pattie Chiang | VP & Corporate Controller | 無 | 無 | 無 |
描述
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
公司管治
截至 2024年5月1日 止，Kezar Life Sciences, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：8；董事會：7；股東權利：8；現金賠償：9。
